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Objectives: To evaluate the impact of The Danish Oxygen Register on COPD
patients’ treatment modalities, survival, and adherence to guidelines for long-term
oxygen therapy (LTOT).
Design: The Danish Oxygen Register.
Subjects: 8487 COPD patients who received LTOT in the study period from
November 1, 1994, to December 31, 2000.
Main outcome measures: Follow-up, smoking status, correct prescription of LTOT
(15–24 h/day), and survival.
Results: During the study period an increasing number of patients were prescribed
LTOT in connection with discharge after hospitalisation for an exacerbation (1995 vs.
2000: 74.4% vs. 82.2%, Po0:001), were prescribed oxygen 15–24 h/day (66.2% vs.
85.5%, Po0:001), had delivered oxygen concentrator or liquid oxygen (77.8%
vs. 96.9%, Po0:001), and had mobile oxygen (29.9% vs. 42.8%, Po0:001). Only 65.8%
of the patients were followed-up in an outpatient clinic with the possibility of re-
evaluation of the criteria for LTOT and adjustment for oxygen flow, with no change
during the study period (P ¼ 0:43). In a representative subsample, 77.1% had
smoking habits or measurement of CO-level registered in 1995 compared to 79.6% in
year 2000 (P ¼ 0:65), and 25.1% vs. 21.2% (P ¼ 0:34) were considered current
smokers. The median survival increased from 1.07 to 1.40 years (P ¼ 0:032).
Conclusions: Adherence to guidelines for LTOT has improved concerning adminis-
tration of oxygen, but has remained poor concerning follow-up of the patients and
smoking cessation. Survival of COPD patients on LTOT has improved during the
observation period.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
23632.
.dk (T.J. Ringbaek).
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Impact of the Danish Oxygen Register 219Guidelines for long-term oxygen therapy (LTOT) are
primarily built on three randomised studies of
patients with hypoxaemic chronic obstructive
pulmonary disease (COPD).1–3 All guidelines focus
on four key issues: (1) COPD patients eligible for
LTOT should have hypoxaemia in a stable condition,
(2) be non-smokers, (3) use oxygen for at least 15 h
daily, and (4) have oxygen treatment re-evaluated
within 3 months after initiation of the therapy.4–8
In 1994, only 35% of the Danish patients adhered
to the criteria for LTOT.4 Similar poor compliance
has been found in other countries.9–15 In order to
improve the quality of LTOT, national oxygen
registers have been established in Sweden and
France.16,17 The Danish Oxygen Register was estab-
lished in 1994.4 In the present paper we focus on
the impact of this register on changes in compli-
ance with LTOT guidelines for COPD patients during
1994 to 2000. In addition we also present data on
incidence, prevalence, and survival of COPD pa-
tients on LTOT.Methods
Collection of information
The Danish Oxygen Register was established in
November, 1994, and covers 98–99% of the Danish
population, which comprises about 5.3 million
inhabitants.4 In the period up until 31 December
2000, 8487 COPD patients have been registered,
including 5659 who started therapy between 01
January 1995 and 31 December 1999. The oxygen
suppliers provided information on the details
regarding administration of oxygen including oxy-
gen flow, daily number of hours on oxygen,
delivered oxygen systems, and possible stop of
therapy. The information on diagnosis came from
the patients’ hospital files, or from The National
Health Services Central Register of Causes of Death
and Hospitalisations. Data on smoking status in
LTOT patients was collected in 1995 (all patients)
and in 2000 (in a representative sub-sample
comprising about 15% of all). Most of the patients
were asked about smoking, and selected patients
had carbon monoxide (CO) measured in their blood
or expired air. Patients were considered smokers if
they admitted to doing so or had blood CO-
haemoglobin43% or CO-level in expired air
410 ppm. Vital status was ascertained by the
National Health Services Central Register up to 31
December 2000. The National Board of Health
provided information on outpatient contacts up to
31 December 1999.The regional Ethical Committees and the Data
Inspection Board have approved the study.
Guidelines and organisation of LTOT in
Denmark
Denmark consists of 16 counties with 45,000–
614,000 inhabitants. Each county has its own
organisation of LTOT. In eight counties the general
practitioners (GP) took part in prescribing home
oxygen. In general, the oxygen suppliers were able
to choose between a concentrator or gas cylinders.
In cases of a high consumption of oxygen it was
more favourable for the suppliers to deliver a
concentrator. Liquid oxygen became available in
July 1995. All costs of oxygen treatment, including
consumption of electricity by oxygen concentra-
tors, are covered by the local hospital. This is also
the case if a GP prescribes oxygen. Neither guide-
lines nor the organisation of domiciliary oxygen
have been changed during the study period.
Implementation of guidelines and access to
data from The Danish Oxygen Register
In the study period, several meetings throughout
Denmark and published papers have focused on the
guidelines for LTOT. Although all prescribing doctors
have access to their own data on requirement, very
few made use of this. Data on prevalence,
incidence, treatment modality, and adherence to
guidelines for LTOT at the start of the register have
been discussed at national conferences.
Statistical analyses
Survival analyses comprised 5659 COPD patients
who started LTOT between 01 January 1995 and 31
December 1999. They were followed until the end
of 2000, and during this period 3935 (69.5%) deaths
were observed. Survival was studied by univariate
analysis (Kaplan–Meier). Cox regression model was
used to determine whether the year of start on
LTOT (1995, 1996, 1997, 1998, or 1999) was an
individual predictor of survival. Covariates in the
multivariate models were as follows: gender,
oxygen flow (continuous variable), age (continuous
variable), delivered mobile oxygen (yes or no),
prescribed oxygen 15–24 h/day (yes or no), and
LTOT prescribed by the hospital doctor or the GP.
Assumption of linearity was assessed by categoris-
ing the variable into multiple dichotomous vari-
ables of equal units on the variable’s scale. The
estimated coefficients of each dichotomous
variable were compared. The hazard ratios for
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T.J. Ringbaek, P. Lange220independent variables were adjusted for those
covariates (confounders), which were related to
survival and to the independent variable. The
results of regression analyses are given in terms
of estimated relative risks (RRs) (hazard ratios),
with corresponding 95% confidence intervals (CIs).
Data analyses and descriptive statistics were
performed with the statistical package for the
social sciences (SPSS) version 12.0 (SPSS Inc.,
Chicago, USA). The w2, two sample t-tests, Man-
n–Whitney U-test and Kruskal–Wallis tests were
used as appropriate to compare differences be-
tween groups. A two-sided P-value of o0.05 was
considered significant.Results
Incidence and prevalence of COPD patients
on LTOT
On the 1st of November 1994, a total of 1354 (26.8
per 100,000 inhabitants) COPD patients received
LTOT. During the following 6 years, the prevalence
of COPD patients on LTOT increased to 42.1 per
100,000. Correspondingly, the annual incidence of
oxygen therapy increased from 20.5 to 25.2 per
100,000 (Fig. 1).
Patients’ characteristics and treatment
modalities
The majority of the COPD patients were females
(Table 1). Among new patients, the mean age
increased from 70.6 to 72.4 years (Po0:001) (Table
1). Most of the COPD patients were prescribed
oxygen therapy by a hospital doctor immediately
after a hospitalisation for an acute exacerbation,
and the number of prescriptions from GP was
declining (Table 1). An increasing number of the
COPD patients were prescribed oxygen at least 15 h0
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Figure 1 Changes in the incidence of LTOT for COPD
patients from 1995 to 2000.daily, had been delivered oxygen concentrator or
liquid oxygen, and had mobile oxygen (Table 1).
The average oxygen flow during the study period
increased (Table 1). During the study period, we
observed no differences in smoking habits and
assessment of smoking (Table 2).
Follow up of LTOT
Despite the fact that a high number of COPD
patients initiated LTOT during an unstable clinical
condition, only 65.8% of those alive after 6 months,
were followed-up in an outpatient clinic in order to
re-evaluate the criteria for LTOT (Table 1). Corre-
spondingly, only 15.4% of the patients alive at 6
months had treatment stopped—without changes
during the study period. This interruption of
therapy was often permanent and only 7.9% of
these patients restarted oxygen therapy within a 6-
month period—again without changes during the
study period.
Survival
The median survival time of LTOT patients was 1.27
years (95% CI: 1.20–1.34) (Fig. 2). Compared to
patients who started LTOT in 1995, the median
survival time was increased by 4 months in those
patients who started LTOT in 1999 (Table 2). The
Cox regression model showed that only age
(decreasing), female gender (relative risk 0.89),
mobile oxygen (relative risk 0.66), and late start on
LTOT were independently associated with de-
creased risk of dying (Table 3). In the univariate
analysis, correct prescribed oxygen (15–24 h daily)
was related to decreased risk of dying (P ¼ 0:004),
but it was not significant in the multivariate model.
Discussion
Using data from The Danish Oxygen Register, we
observed following trends in the late 90s in the
LTOT for COPD: (1) the incidence and prevalence
increased, (2) the mean age of the patients
increased, patients had mobile oxygen prescribed
more often, and LTOT was less often initiated by
GPs, (3) in general the quality of treatment
improved in regard to prescription of oxygen
415 h/day, whereas adherence to guidelines for
smoking cessation and follow-up has not improved,
and (4) finally, taken the increasing age of the
patients into account, survival has improved during
the study period.
Previous studies from Sweden and France demon-
strated increasing prevalence of COPD patients on
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Table 2 Smoking status of COPD patients, residing in the central part of Copenhagen, and on LTOT in 1995 and
2000, respectively.
1995 n ¼ 240 2000 n ¼ 279 P-level for difference
Asked about smoking 180(75.0%) 216(77.4%) 0.52
Admitted smoking (% of asked patients) 34(20.4%) 32(15.5%)y 0.23
Measured CO 136(56.7%) 141(50.5%) 0.16
Abnormal value (% of checked patients) 21(15.4%) 19(15.8%) 0.64
Asked about smoking or measured CO-level 187(77.1%) 222(79.6%) 0.65
Indication of smoking (% of asked or checked patients) 47(25.1%) 47(21.2%) 0.34
Thirteen cases of ‘‘don’t know’’
yTen cases of ‘‘don’t know’’.
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Figure 2 Survival rates of new COPD patients on LTOT
from Denmark compared to patients from other coun-
tries. The crude mortality of Danish patients stem from
13 appointed data sets of a Kaplan–Meier plot. Data from
the other countries originate from Refs. 2, 26–30.
T.J. Ringbaek, P. Lange222LTOTup to the mid 90s.16–19 In France, according to
the ANTADIR register, which comprises some 70% of
all French patients on LTOT, the prevalence
increased from about 4 to 28 per 100,000 from
1983 to 1992.16–19 In Sweden, the prevalence
doubled to 11 per 100,000 between 1987 and
1993.17,18 In Denmark in the same period, the
prevalence increased from approximately 12 to
26.8 per 100,000. In the following years, we found
that the prevalence of LTOT in COPD patientsincreased further by 57% and reached 42.1 per
100,000.
There are at least two explanations for this
finding. Firstly, COPD has become more prevalent in
Denmark, which is also reflected by increased
hospitalisations and mortality. From 1994 to 2000,
the age-standardised hospitalisation rate for COPD
has increased from 300 to 450 per 100,000 (data
from The National Board of Health). In the same
period, the age-standardised mortality rates for
COPD mortality have increased from 70 to 82 per
100,000 (data from The National Health Services
Central Register in Denmark). Secondly, more
patients start LTOT in a clinically unstable condi-
tion, immediately after a hospitalisation without a
proper follow-up. Follow-up of LTOT patients is
important and may, in fact, have influence on the
prevalence of the treatment. Both the National
Oxygen Treatment Trial study and a study by Levi-
Valensi et al. described the spontaneous evolution
of blood gases after an COPD exacerbation.2,20
They found that about 30–50% of patients initially
hypoxaemic and classified as clinically stable
improved their blood gases and did not fulfil the
hypoxaemia criteria at re-evaluation 2–3 months
later. Therefore, a reassessment is recommended
after 1–3 months of treatment in order to stop LTOT
in patients who are no longer hypoxaemic.5–8 We
found that focus on this particular recommendation
has not improved. Similar low follow-up rates were
found in other countries.21–23 Silverman et al.21
found that only 27% of their patients, who started
oxygen therapy in 1992, had either oximetry or
arterial blood gas measured at least once during
the following year. In another American study,
Oba et al. found that among patients who
started oxygen treatment immediately after dis-
charge from the hospital, only 35% were appro-
priately re-evaluated within the recommended
3-month interval.22 In a Scottish study, blood gas
ARTICLE IN PRESS
Table 3 Relative risks (RR) of mortality with 95% confidence intervals (CI) in 5.659 COPD patients on LTOT
according to year of start
Multivariate P-value
Age, per 1 year decreasing 0.96(0.96–0.97) o0.001
Gender; (male ¼ 1) 0.89(0.83–0.94) o0.001
Mobile oxygen (1 ¼ no) 0.66(0.62–0.71) o0.001
Year of start on LTOT 0.008
1995 1
1996 1.04(0.95–1.15)
1997 0.95(0.86–1.04)
1998 0.89(0.80–0.98)
1999 0.90(0.80–1.00)
Only variables with a statistical association to survival are shown.
Results of a multivariate analysis with Cox proportional hazards model, after adjustment for age, gender, correct prescribed
number of hours on oxygen, and mobile oxygen.
Impact of the Danish Oxygen Register 223measurements were repeated within 1 year in 56%
of the patients—half of these during a clinically
unstable condition.23
During the study period the quality of LTOT has
improved: significantly more patients are now
treated at least 15 h daily. Previously, we have
shown a close correlation between prescribed and
used oxygen and, therefore, we assume that the
correct prescription results in more hours on
oxygen for the individual patient.24 Furthermore,
an increasing number of COPD patients were
equipped with an oxygen concentrator, which is
the preferable oxygen system when patients use
oxygen continuously. In addition more patients are
offered mobile oxygen which further promotes
continuous administration of oxygen and facilitates
outdoor activity.25
As recommended by the most recent British
guidelines, we found that fewer patients had
oxygen therapy prescribed by GP, who are unable
to measure blood gases and unlikely to obtain
sufficient experience in this therapy.8
Although the beneficial effect of LTOTon survival
in the MRC and NOTT study was not restricted to
non-smokers, most guidelines on LTOT, including
the Danish guidelines, exclude smokers.1,2,4 Smo-
kers are excluded in order to optimise the clinical
status, to increase the number of hours on oxygen
therapy, to avoid risk of fire and burns, and finally
morale reasons may also play a role. However, at
the time when we established the Danish Oxygen
Register, a lot of our COPD patients were smokers,
and this number does not seem to go down. As the
CO-level in blood or expired air is not checked
routinely in many of the patients, the number of
patients who smoke may be even higher than the20–25% we estimated in the subgroup of the
Copenhagen patients (Table 2).
The survival of our COPD patients was substan-
tially lower than in other countries (Fig. 2). After 1
year, only 55.5% of our patients were still alive
compared to 70–88% in other studies. 2,26–30 Best
survival has been reported in the NOTT study where
patients were younger and had no concomitant
diseases.2 Although the mean age of the patients in
the French, Australian, and Japanese study was
comparable to our patients, the 1-year survival
rates in these studies were markedly better than in
our patients, 81%, 75%, and 88%, respec-
tively.27,28,30 This difference in mortality is mainly
due to a much higher 3 months mortality in our
study (Fig. 2). Most of our patients started LTOT in
an unstable clinical condition right after a hospital
admission. Studies have shown that COPD patients
who have been discharged from the hospital,
regardless of prescribed LTOT, have a 3 months
mortality of 20–25%.31,32 In the NOTT and MRC
studies, a period of 3 months with clinical stable
condition was ensured.1,2 In Belgium, Sweden, and
Japan a minimum period of 3–4 weeks of assessing
the stability of hypoxaemia was recom-
mended.26,29,30 Whether this was actually prac-
ticed is not reported. However, it seems that most
of the Swedish patients started LTOT in a clinically
stable condition, because only 4% had LTOT stopped
within 2 years due to normalisation of blood
gases.29 Therefore, we believe that the different
practice in starting LTOT (stable or unstable
condition) may explain the higher 3-month mortal-
ity in our patients compared to patients in the
other studies.26–30 In addition, our patients may
have started LTOT with a more advanced disease.
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hospitalised before LTOT, were often on systemic
corticosteroids, and were often unable to under-
take outdoor activities—all suggesting severe dis-
ease.33,34 Therefore, in order to detect these
hypoxaemic patients as early as possible, GPs
should be encouraged to either perform pulse
oximetry or refer all COPD patients with FEV1 less
than 50% of predicted value to the hospital or
special laboratories capable of measuring blood
gases.
Although the mean age of our COPD patients has
increased by almost 2 years, the survival rate has
improved. This could be due to either better
treatment or enrolment of less severe COPD
patients. Supporting the first hypothesis, more
patients seemed to use oxygen 15–24 h daily.
Supporting the second hypothesis, the increasing
number of patients with mobile oxygen may
indicate that these patients had a less severe
disease. However, after adjusting for the above-
mentioned covariates, our findings did not change.
Thus far, the only treatments that have been shown
to make a difference to survival in COPD patients
are smoking cessation and LTOT. In our study,
smoking status has not changed. Inhaled corticos-
teroids were prescribed to approximately 40% of
our COPD patients who started LTOT in 1995.34 This
number may have increased during the study
period, but any effect of this change on survival is
controversial.35 In our analysis of predictors of
survival, we were not able to adjust for body mass
index, lung function, co-morbidity, and packyears
of smoking, which may have changed in the study
period.
In conclusion, using 6 years of data from The
Danish Oxygen Register, we found adherence to
guidelines for LTOT for COPD has improved con-
cerning administration of oxygen, but has remained
poor concerning follow-up and smoking cessation in
treated patients.References
1. Medical Research Council Working Party. Report of long-term
domiciliary oxygen therapy in chronic hypoxic cor pulmonale
complicating chronic bronchitis and emphysema. Lancet
1981;1:681–5.
2. Nocturnal Oxygen Therapy trial Group. Continuous or
nocturnal oxygen therapy in hypoxemic chronic obstructive
lung disease. Ann Intern Med 1980;93:391–8.
3. Go´recka D, Gorzelak K, Sliwinski P, Tobiasz M, Zielinski J.
Effect of long term oxygen therapy on survival in patients
with chronic obstructive pulmonary disease with moderate
hypoxaemia. Thorax 1997;52:674–9.
4. Ringbaek TJ, Lange P, Viskum K. Geographical variation in
long-term oxygen therapy in Denmark. Factors related toadherence to guidelines for long-term oxygen therapy. Chest
2001;119:1711–6.
5. ATS Statement. Standards for the diagnosis and care of
patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 1995;152:S77–S120.
6. Tzanakis N, Mitrouska I, Siafakas NM. Oxygen therapy in
chronic obstructive pulmonary disease. Eur Respir Mon
1998;7:169–79.
7. BTS Guidelines for the Management of Chronic Obstructive
Pulmonary Disease. Thorax 1997;52(5 Suppl):1S–27S.
8. Wedzicha JA. Domiciliary oxygen therapy services: clinical
guidelines and advice for prescribers. J R Coll Physicians
Lond 1999;33:445–7.
9. Granados A, Escarrabill J, Borra`s JM, Rodriguez-Roisin R. The
importance of process variables analysis in the assessment of
long-term oxygen therapy by concentrator. Respir Med
1997;91:89–93.
10. Kampelmacher MJ, Kersteren RG, Alsbach GPJ, et al.
Prescription and usage of long-term-oxygen therapy in
patients with chronic obstructive pulmonary disease in the
Netherlands. Respir Med 1999;93(1):46–51.
11. Dilworth JP, Higgs CMB, Jones PA, White RJ. Prescription of
oxygen concentrators: adherence to published guidelines.
Thorax 1989;44:576–8.
12. Bellone A, Venanzi D, De Angelis G, et al. Who should
prescribe long-term oxygen in patients affected by chronic
arterial hypoxaemia? Monaldi Arch Chest Dis 1994;
49(5):396–8.
13. Waterhouse JC, Nichol J, Howard P. Survey on domiciliary
oxygen by concentrator in England and Wales. Eur Respir J
1994;7(11):2021–5.
14. Walshaw MJ, Lim R, Evans CC, Hind CR. Prescription of
oxygen concentrators for long term oxygen treatment:
reassessment in one district. BMJ 1988;297:1030–2.
15. Restrick LJ, Paul EA, Braid GM, Cullinan P, Moore-Gillon J,
Wedzicha JA. Assessment and follow up of patients
prescribed long term oxygen treatment. Thorax 1993;48:
708–13.
16. Chailleux E, Fauroux B, Binet F, Dautzenberg B, Polu JM, for
the Observatory Group of ANTADIR. Predictors of survival in
patients receiving domiciliary oxygen therapy or mechanical
ventilation. A 10-year analysis of ANTADIR observatory.
Chest 1996;109:741–9.
17. Stro¨m K, Boe J. A national register for long-term oxygen
therapy in chronic hypoxia: preliminary results. Eur Respir J
1988;1:952–8.
18. Stro¨m K, Olofsson J, Skoogh B-E. Current status of home
oxygen therapy in Sweden. In: Kira S, Petty TL, editors.
Progress in domiciliary respiratory care. Current status and
perspective. Amsterdam: Elsevier Science BV; 1994. p. 71–8.
19. Muir JF, Voisin C, Ludot A. Organization of home respiratory
care: the experience in France with ANTADIR. Monaldi Arch
Chest Dis 1993;48(5):462–7.
20. Levi-Valensi P, Weitzenblum E, Pedinielli J-L, Racineux JL,
Duwoos H. Three-month follow-up of arterial blood gas
determinations in candidates for long-term oxygen therapy.
Am Rev Respir Dis 1986;133:547–51.
21. Silverman BG, Gross TP, Babish JD. Home oxygen therapy in
Medicare beneficiaries, 1991 and 1992. Chest 1997;112:380–6.
22. Oba Y, Salzman GA, Willsie SK. Reevaluation of continuous
oxygen therapy after initial prescription in patients with
chronic obstructive pulmonary disease. Respir Care 2000;
45:401–6.
23. Morrison D, Skwarski K, MacNee W. Review of the prescrip-
tion of domiciliary long term oxygen therapy in Scotland.
Thorax 1995;50:1103–5.
ARTICLE IN PRESS
Impact of the Danish Oxygen Register 22524. Ringbaek T, Lange P, Viskum K. Compliance with LTOT and
consumption of mobile oxygen. Respir Med 1999;93:
333–7.
25. Pe´pin J-L, Barjhoux CE, Deschaux C, et al. (ANTADIRWorking
Group on Oxygen Therapy). Long-term oxygen therapy at
home. Chest 1996;109:1144–50.
26. Dubois P, Jamart J, Machiels J, et al. Prognosis of severely
hypoxemic patients receiving long-term oxygen therapy.
Chest 1994;105:469–74.
27. Foucher P, Baudouin N, Merati M, et al. Relative survival
analysis of 252 patients with COPD receiving long-term
oxygen therapy. Chest 1998;113:1580–7.
28. Crockett AJ, Cranston JM, Moss JR, Alpers JH. Survival on
long-term oxygen therapy in chronic airflow limitation: from
evidence to outcomes in the routine clinical setting. Intern
Med J 2001;31:448–54.
29. Stro¨m K, Boe J, Boman G, Midgren B, Rosenhall L. Long-term
domiciliary oxygen therapy. Experiences acquired from the
Swedish oxygen register. Monaldi Arch Chest Dis 1993;48:
473–8.
30. Aida A, Miyamoto K, Nishimura M, et al. Prognostic value of
hypercapnia in patients with chronic respiratory failureduring long-term oxygen therapy. Am J Respir Crit Care Med
1998;158:188–93.
31. Connors Jr. AF, Dawson NV, Thomas C, et al. Outcomes
following acute exacerbation of severe chronic obstructive
lung disease. The SUPPORT investigators (study to under-
stand prognoses and preferences for outcomes and risks of
treatments). Am J Respir Crit Care Med 1996;154(4 Part 1):
959–67.
32. Nanna E, Hansen EF, Munch EP, Rasmussen FV, Vestbo J.
Chronic obstructive pulmonary disease—admission and prog-
nosis. Ugeskr Laeger 2003;165(37):3499–502 (in Danish).
33. Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen
therapy reduce hospitalisation in hypoxaemic chronic
obstructive pulmonary disease? Eur Respir J 2002;20(1):
38–42.
34. Ringbaek TJ, Viskum K, Lange P. BMI and oral glucocorticoids
as predictors of prognosis in COPD patients on LTOT. Chronic
Respir Dis 2004;1(2):71–8.
35. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC.
Survival in COPD patients after regular use of fluticasone
propionate and salmeterol in general practice. Eur Respir J
2002;20(4):819–25.
